Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia

and 6 months after the end of therapy and in 5 out of 10 patients a >50% reduction of bone marrow HC infiltration was recorded. Interpretation and Conclusions. On the basis of these preliminary results observed in 10 patients with progressed HCL, it appears that treatment with anti-CD20 MoAb is safe and effective in at least 50% of patients, particularly in those with a less evident bone marrow infiltration ( ≤ 50%) and in those previously splenectomized.

[1]  W. Wilson,et al.  Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. , 2001, The New England journal of medicine.

[2]  M. Hoffman,et al.  Bone marrow remission of hairy cell leukaemia induced by rituximab (anti‐cd20 monoclonal antibody) in a patient refractory to cladribine , 2000, British journal of haematology.

[3]  W. Wilson,et al.  Responses in refractory hairy cell leukemia to a recombinant immunotoxin. , 1999, Blood.

[4]  B. Coiffier.  Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma patients. , 1999, Haematologica.

[5]  V. Diehl,et al.  Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.

[6]  J. Connors,et al.  Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Ginaldi,et al.  Levels of expression of CD19 and CD20 in chronic B cell leukaemias. , 1998, Journal of clinical pathology.

[9]  P. Zinzani,et al.  Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey , 1997, Leukemia.

[10]  A. Rademaker,et al.  Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. , 1996, Blood.

[11]  M. Grever,et al.  Long-term follow-up of patients with hairy cell leukemia after treatment with 2'-deoxycoformycin. , 1994, Blood.

[12]  D. Carson,et al.  Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. , 1990, The New England journal of medicine.

[13]  M. O’connell,et al.  Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin). , 1987, The New England journal of medicine.

[14]  M. Ratain,et al.  Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Pileri,et al.  Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. , 2000, Haematologica.

[16]  P. Zinzani,et al.  Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. , 1999, Haematologica.

[17]  L. Gordon,et al.  Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Catovsky,et al.  Long term results with 2'deoxycoformycin in hairy cell leukemia. , 1994, Leukemia & lymphoma.

[19]  Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia. , 1987, Leukemia.